TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year ended December 31, 2025 and provided a corporate update. The past year marked a significant milestone in Spectral’s clinical and regulatory progression, highlighted by the completion of enrollment of the Tigris trial, the release of p ...

Tigris publication confirms positive results for primary and key secondary endpoints with 95.3% and 99.4% probability of benefit for PMX at 28-day and 90-day mortality After adjusting for baseline severity, absolute risk reduction for mortality of 10.3% at 28-days and 15.5% at 90-daysSafety profile consistent with standard of care with no significant difference in adverse eventsTigris trial results to be presented at the Society of Critical Care Medicine (“SCCM”) in Chicago, Ill. on March 24, 2026 TORONTO ...

Tigris publication confirms positive results for primary and key secondary endpoints with 95.3% and 99.4% probability of benefit for PMX at 28-day and 90-day mortality After adjusting for baseline severity, absolute risk reduction for mortality of 10.3% at 28-days and 15.5% at 90-daysSafety profile consistent with standard of care with no significant difference in adverse eventsTigris trial results to be presented at the Society of Critical Care Medicine (“SCCM”) in Chicago, Ill. on March 24, 2026  TORONTO ...

BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair SEC-Qualified Financial Expert and Life Sciences Veteran Brings 29 Years of Accounting Leadership to the BoardPompano Beach, Fla, March 23, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced the appointment of J ...

Strengthening Capital Structure and Advancing Clinical Development Strategy Palm Beach Gardens, FL, March 23, 2026 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative” or the “Company”), a development-stage biomedical company focused on novel treatments for degenerative eye diseases, today announced a reverse stock split (“Reverse Stock Split”) of its common stock at a ratio of 1-for-150. The Reverse Stock Split became effective at 12:00 a.m. Eastern Time on March 23, 2026, and the Compa ...

Sera Prognostics Inc. (NASDAQ:SERA) Earnings Report HighlightsSera Prognostics Inc. (NASDAQ:SERA) reported Q4 EPS of -$0.16, surpassing the Zacks Consensus Estimate of -$0.17.Q4 2025 revenue was $10,000, missing estimates (by ~75% per Zacks) and declining from $24,000 in Q4 2024.Sera Prognostics Inc. (NASDAQ:SERA), known as The Pregnancy Company, focuses on improving maternal and neonatal health through innovative pregnancy biomarker information. The company reported its earnings for the fourth quarter of 2 ...

Core Insights - The discussion highlights the evolution of a company's technology and its recent product launches in the vascular trauma sector, indicating a positive trajectory in clinical success and market engagement [1] Group 1: Product Launch and Market Engagement - The company successfully launched products targeting vascular trauma, dialysis, and CABG (coronary artery bypass grafting) over the past year, generating excitement and demonstrating clinical success [1] - There have been learnings and course corrections made during the year, suggesting an adaptive approach to market challenges and product development [1] Group 2: Future Outlook - The company is preparing to enter 2026 with insights gained from previous experiences, indicating a focus on continuous improvement and strategic planning for future growth [1]

Core Insights - Kuros Biosciences achieved a significant 72% year-over-year sales growth, reaching USD 146.1 million for the year 2025, driven primarily by strong performance in Direct MagnetOs sales [2][4][6]. Financial Highlights - Total group revenue for 2025 was USD 146.1 million, an increase of USD 60.9 million from 2024 [2][6]. - Direct MagnetOs sales rose by 71% to USD 143.9 million, compared to USD 84.3 million in 2024 [2][6]. - EBITDA increased to USD 12.4 million in 2025, up from USD 2.4 million in 2024, with adjusted EBITDA reaching USD 19.6 million and a margin of 13.4% [3][6]. - The company reported its first-ever net profit of USD 2.6 million in 2025, compared to a net loss of USD 4.8 million in 2024 [3][6]. Operational Highlights - The company expanded its commercial reach and introduced new products while maintaining operational discipline [4]. - Kuros initiated commercial expansion into the USD 1.3 billion extremities market and enrolled the first patient in a significant clinical trial [7]. - The FDA granted clearance for the MagnetOs MIS Delivery System, supporting minimally invasive surgery [7][8]. Cost Structure - Cost of goods sold amounted to USD 18.6 million in 2025, up from USD 15.2 million in 2024 [9]. - Sales and marketing costs increased significantly from USD 50.7 million in 2024 to USD 84.5 million in 2025, reflecting the growth in commercial activities [10]. - Research and development costs rose from USD 7.9 million in 2024 to USD 10.7 million in 2025, driven by increased clinical trial expenditures [11]. Financial Position - Cash and cash equivalents stood at USD 19.8 million, with total funds available for operations amounting to USD 60.0 million as of December 31, 2025 [12]. - Total intangible assets were USD 16.6 million, and goodwill was USD 24.3 million as of December 31, 2025 [13]. Future Outlook - Kuros expects at least 35% sales growth in 2026, with an adjusted EBITDA margin of around 14% [6][14]. - By 2028, the company anticipates sales of USD 300 to 330 million, with an adjusted EBITDA margin of at least 20% [6][14].

Group 1 - Generate Biomedicines (GENB) priced its IPO at the midpoint [2] - One IPO and six SPACs came to market in the past week [2] - A major issuer joined the pipeline as February comes to a close [2]

Group 1 - The A-share market opened lower with all three major indices declining, with the Shanghai Composite Index down 0.43%, the Shenzhen Component down 0.89%, and the ChiNext Index down 1.23% [2][3] - The CPO, optical fiber, energy metals, and semiconductor sectors experienced significant declines, while the tourism, hotel, and port shipping sectors saw slight gains [2][3] - The Hong Kong market opened with the Hang Seng Index up 0.25% and the Hang Seng Tech Index up 0.15%, driven by strong performance in the biopharmaceutical sector [4] Group 2 - The central bank conducted a 7-day reverse repurchase operation of 269 billion yuan at an interest rate of 1.40%, with no reverse repos maturing today [4] - The RMB to USD central parity rate was reported at 6.9228, unchanged from the previous trading day [4]